• aTyr Pharma announced publication of Phase 3 EFZO-FIT results for efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine.
• The 48-week trial in 268 patients missed its primary goal of reducing steroid use significantly compared with placebo.
• Efzofitimod improved patient-reported outcomes, maintained lung function and was generally well tolerated.
• Study-related activities have begun for another global Phase 3 trial in pulmonary sarcoidosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290800PRIMZONEFULLFEED9855629) on October 29, 2026, and is solely responsible for the information contained therein.